Literature DB >> 22306231

Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.

Randi-Michelle Cowin1, Ana Roscic, Nghiem Bui, Deanna Graham, Paolo Paganetti, Joanna L Jankowsky, Andreas Weiss, Richard Paylor.   

Abstract

Huntington's disease (HD) is caused by the expansion of the polyglutamine tract expressed in the huntingtin protein. Data from patients show a strong negative correlation between CAG repeat size and age of disease onset. Recent studies in mixed background C57×CBA R6/2 mice suggest the inverse correlation observed in the human disease may not be replicated in some animal models of HD. To further clarify the relationship between repeat length and age of onset, congenic C57BL6/J R6/2 transgenic mice expressing 110, 260 or 310 CAG were tested in a comprehensive behavioral battery at multiple ages. Data confirmed the findings of earlier studies and indicate that on a pure C57BL6/J genetic background, R6/2 mice with larger repeats exhibit a delay in phenotypic onset with increasing polyglutamine size (6 weeks in 110 CAG and 17 weeks in 310 CAG mice). Further analysis confirmed a decrease in transgene transcript expression in 310 CAG mice as well as differential aggregated protein localization in association with repeat length. Mice expressing 110 CAG developed aggregates that localized almost exclusively to the nucleus of neuronal cells in the striatum and cortex. In contrast, tissue from 310 CAG mice exhibited predominantly extranuclear inclusions. Novel mutant protein analysis obtained using time-resolved fluorescence resonance energy transfer (FRET) revealed that soluble protein levels decreased with disease onset in R6/2 mice while aggregated protein levels increased. We believe that these data suggest a role for aggregation and inclusion localization in HD pathogenesis and propose a mechanism for the age of onset delay observed in R6/2 mice.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22306231     DOI: 10.1016/j.bbr.2011.12.045

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  7 in total

Review 1.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

2.  Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.

Authors:  Marta Anglada-Huguet; Xavier Xifró; Albert Giralt; Alfonsa Zamora-Moratalla; Eduardo D Martín; Jordi Alberch
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

3.  HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Authors:  Miriam Moscovitch-Lopatin; Rachel E Goodman; Shirley Eberly; James J Ritch; H Diana Rosas; Samantha Matson; Wayne Matson; David Oakes; Anne B Young; Ira Shoulson; Steven M Hersch
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

4.  Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.

Authors:  Huu Phuc Nguyen; Jeannette Hübener; Jonasz Jeremiasz Weber; Stephan Grueninger; Olaf Riess; Andreas Weiss
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

5.  Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.

Authors:  Liliana B Menalled; Andrea E Kudwa; Steve Oakeshott; Andrew Farrar; Neil Paterson; Igor Filippov; Sam Miller; Mei Kwan; Michael Olsen; Jose Beltran; Justin Torello; Jon Fitzpatrick; Richard Mushlin; Kimberly Cox; Kristi McConnell; Matthew Mazzella; Dansha He; Georgina F Osborne; Rand Al-Nackkash; Gill P Bates; Pasi Tuunanen; Kimmo Lehtimaki; Dani Brunner; Afshin Ghavami; Sylvie Ramboz; Larry Park; Douglas Macdonald; Ignacio Munoz-Sanjuan; David Howland
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

Review 6.  The Contribution of Somatic Expansion of the CAG Repeat to Symptomatic Development in Huntington's Disease: A Historical Perspective.

Authors:  Darren G Monckton
Journal:  J Huntingtons Dis       Date:  2021

7.  A huntingtin peptide inhibits polyQ-huntingtin associated defects.

Authors:  Yoan Arribat; Nathalie Bonneaud; Yasmina Talmat-Amar; Sophie Layalle; Marie-Laure Parmentier; Florence Maschat
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.